<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Abbott Laboratories (ABT) — Investment Wiki</title>
  <meta name="description" content="Fundamental analysis of Abbott Laboratories (ABT). Business model breakdown, revenue segments, valuation metrics, and investment thesis.">
  <meta property="og:title" content="Abbott Laboratories (ABT) — Investment Wiki">
  <meta property="og:description" content="Fundamental analysis of Abbott Laboratories (ABT). Business model breakdown, revenue segments, valuation metrics, and investment thesis.">
  <meta property="og:type" content="article">
  <meta name="robots" content="index, follow">
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect width='100' height='100' rx='20' fill='%230091DA'/><text x='50' y='68' font-family='Arial' font-size='55' font-weight='bold' fill='white' text-anchor='middle'>A</text></svg>">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="../../docs/docs-styles.css">
</head>
<body>

<div class="doc-container">

  <nav class="doc-breadcrumb">
    <a href="../../index.html">Home</a>
    <span class="sep">/</span>
    <a href="../index.html">Investment</a>
    <span class="sep">/</span>
    Abbott Laboratories (ABT)
  </nav>

  <header class="doc-header">
    <h1 class="doc-title">Abbott Laboratories (ABT)</h1>
    <div class="doc-meta">
      <span class="tag">Company Analysis</span>
      <span>Investment Wiki — Fundamentals</span>
    </div>
  </header>

  <div class="doc-abstract">
    Abbott Laboratories (ABT) is a diversified global healthcare company with a portfolio spanning medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. Known for its steady growth and over 50 years of consecutive dividend increases (a Dividend King), Abbott combines the stability of consumer staples with the innovation of a medical technology leader.
  </div>

  <div class="doc-content">

    <div class="gab-stack-infobox">
      <div class="infobox-header">Quick Reference</div>
      <table>
        <tr><td>Ticker</td><td>ABT</td></tr>
        <tr><td>Sector</td><td>Healthcare</td></tr>
        <tr><td>Market Cap</td><td>~$200 Billion</td></tr>
        <tr><td>P/E Ratio</td><td><span class="complexity-medium">~25–30x</span></td></tr>
        <tr><td>ROE</td><td><span class="complexity-medium">~13–20%</span></td></tr>
        <tr><td>Revenue Growth</td><td>~5-7% (Organic)</td></tr>
        <tr><td>Operating Margin</td><td><span class="complexity-medium">~16–19%</span></td></tr>
      </table>
    </div>

    <section class="doc-section">
      <h2>1.0 Business Overview</h2>

      <p>Abbott operates through four primary segments, providing a balanced revenue stream that mitigates risk in any single area.</p>

      <h3>Medical Devices</h3>
      <p>The primary growth engine (~45% of revenue). Key products include:</p>
      <ul>
        <li><strong>FreeStyle Libre:</strong> A market-leading Continuous Glucose Monitoring (CGM) system for diabetes management.</li>
        <li><strong>Structural Heart:</strong> Devices like MitraClip for heart valve repair.</li>
        <li><strong>Rhythm Management:</strong> Pacemakers and ICDs.</li>
      </ul>

      <h3>Diagnostics</h3>
      <p>A major revenue contributor (~25% of revenue). Includes:</p>
      <ul>
        <li><strong>Core Laboratory:</strong> The Alinity family of systems used in hospitals and labs.</li>
        <li><strong>Rapid Diagnostics:</strong> Point-of-care testing (e.g., BinaxNOW for COVID-19, though volumes are normalizing).</li>
      </ul>

      <h3>Nutrition</h3>
      <p>A steady cash generator (~18% of revenue). Includes:</p>
      <ul>
        <li><strong>Pediatric:</strong> Similac (infant formula) and Pediasure.</li>
        <li><strong>Adult:</strong> Ensure and Glucerna.</li>
      </ul>

      <h3>Established Pharmaceuticals (EPD)</h3>
      <p>Focuses on branded generics in emerging markets (~12% of revenue). This segment provides access to high-growth regions like India, Russia, and Latin America, where branded generics command loyalty and pricing power.</p>
    </section>

    <section class="doc-section">
      <h2>2.0 Financial Performance</h2>

      <h3>Dividend King Status</h3>
      <p>Abbott is a Dividend King, having increased its dividend for over 50 consecutive years. This demonstrates a strong commitment to returning capital to shareholders and a resilient business model.</p>

      <h3>Margins</h3>
<pre><code><span class="code-label">reference</span>Gross Margin:      ~55%
Operating Margin:  ~18%
Net Margin:        ~14%

Key Driver: Medical Devices provides the highest margin profile,
offsetting lower margins in Nutrition and EPD.</code></pre>

    </section>

    <section class="doc-section">
      <h2>3.0 Valuation</h2>

      <p>Abbott typically trades at a premium to the broader market and some healthcare peers due to its "best-in-class" quality, diversification, and dividend history.</p>

      <h3>Valuation Metrics</h3>
      <table>
        <thead>
          <tr><th>Metric</th><th>Typical Range</th><th>Interpretation</th></tr>
        </thead>
        <tbody>
          <tr><td><strong>P/E Ratio</strong></td><td>25x – 30x</td><td>Premium valuation reflecting stability and quality.</td></tr>
          <tr><td><strong>PEG Ratio</strong></td><td>2.0 – 2.5</td><td>High, but often justified by low volatility and reliable growth.</td></tr>
          <tr><td><strong>FCF Yield</strong></td><td>~3%</td><td>Consistent cash generation supports the growing dividend.</td></tr>
        </tbody>
      </table>

      <div class="callout callout-note">
        When valuing Abbott, consider the "quality premium." Investors often pay up for the safety of its diversified portfolio and the reliability of its dividend, especially during economic uncertainty.
      </div>
    </section>

    <section class="doc-section">
      <h2>4.0 Risks</h2>

      <h3>Litigation</h3>
      <p>Like many healthcare giants, Abbott faces legal risks. Specifically, lawsuits regarding Necrotizing Enterocolitis (NEC) in premature infants fed with cow's milk-based formula (Similac) have created an overhang on the stock.</p>

      <h3>Foreign Exchange (FX)</h3>
      <p>With a significant portion of sales coming from outside the U.S. (especially in Established Pharmaceuticals), a strong U.S. dollar can negatively impact reported revenue and earnings.</p>

      <h3>Pricing Pressure</h3>
      <p>Global healthcare systems are under pressure to reduce costs. Initiatives like China's Volume-Based Procurement (VBP) can compress margins for medical devices and pharmaceuticals in key markets.</p>
    </section>

    <section class="doc-section">
      <h2>5.0 Related Pages</h2>

      <div class="integration-grid">
        <div class="integration-card">
          <h4><a href="../price-to-earnings-ratio.html">P/E Ratio</a></h4>
          <p>Understand why quality companies like Abbott trade at a premium.</p>
        </div>
        <div class="integration-card">
          <h4><a href="../dividend-growth-rate.html">Dividend Growth</a></h4>
          <p>Learn about the power of compounding dividends over 50+ years.</p>
        </div>
        <div class="integration-card">
          <h4><a href="../return-on-equity.html">Return on Equity</a></h4>
          <p>Analyze how efficiently Abbott uses shareholder capital.</p>
        </div>
      </div>
    </section>

  </div>

  <footer class="doc-footer">
    <a href="../index.html">← Back to Investment Wiki</a>
    <span style="color: var(--text-tertiary);">Investment Wiki</span>
  </footer>

</div>

</body>
</html>
